Evidence map›Paper›PMID 25710356›Full record

ArticleNucleosides, nucleotides & nucleic acids2015

Design, synthesis and evaluation of Fe-S targeted adenosine 5'-phosphosulfate reductase inhibitors.

Hanumantharao Paritala, Yuta Suzuki, Kate S Carroll

Abstract read
In one paragraph

Article in Nucleosides, nucleotides & nucleic acids, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Fe-S Clusters Emerging as Targets of Therapeutic Drugs.Oxidative medicine and cellular longevity · 2017
    Review
  4. Functional Site Discovery in a Sulfur Metabolism Enzyme by Using Directed Evolution.Chembiochem : a European journal of chemical biology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hanumantharao Paritalaa Department of Chemistry, The Scripps Research Institute , Jupiter , Florida , USA.
Yuta Suzuki
Kate S Carroll
Scripps Research Institute · USUniversity of Michigan–Ann Arbor · US

Funding

Sulfur Metabolism in Human PathogensR01GM087638 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARROLL, KATE SUZANNE · 2009 to 2025
$5.0M
NIGMS NIH HHS GM087638NIGMS NIH HHS R01 GM087638
6 · The paper itself

Abstract

Adenosine 5'-phosphosulfate reductase (APR) is an iron-sulfur enzyme that is vital for survival of Mycobacterium tuberculosis during dormancy and is an attractive target for the treatment of latent tuberculosis (TB) infection. The 4Fe-4S cluster is coordinated to APR by sulfur atoms of four cysteine residues, is proximal to substrate, adenosine 5'-phopsphosulfate (APS), and is essential for catalytic activity. Herein, we present an approach for the development of a new class of APR inhibitors. As an initial step, we have employed an improved solid-phase chemistry method to prepare a series of N(6)-substituted adenosine analogues and their 5'-phosphates as well as adenosine 5'-phosphate diesters bearing different Fe and S binding groups, such as thiols or carboxylic and hydroxamic acid moieties. Evaluation of the resulting compounds indicates a clearly defined spacing requirement between the Fe-S targeting group and adenosine scaffold and that smaller Fe-S targeting groups are better tolerated. Molecular docking analysis suggests that the S atom of the most potent inhibitor may establish a favorable interaction with an S atom in the cluster. In summary, this study showcases an improved solid-phase method that expedites the preparation of adenosine and related 5'-phosphate derivatives and presents a unique Fe-S targeting strategy for the development of APR inhibitors.

Indexed as

Drug DesignEnzyme InhibitorsIronModels, MolecularMolecular ConformationOxidoreductases Acting on Sulfur Group DonorsSolid-Phase Synthesis TechniquesSulfuradenylylsulfate reductaseEnzyme InhibitorsIronOxidoreductases Acting on Sulfur Group DonorsSulfurAntibacterial nucleosidesenzyme inhibitionsolid phase synthesis

Identifiers

PMID25710356
PMCPMC4341950
OpenAlexW1993315276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.